Search Results for "Benzodiazepine Multiple Sclerosis"

16:44 EDT 18th April 2015 | BioPortfolio

Matching Channels

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...

Systemic Sclerosis

Diffuse mesangial sclerosis

Amyotrophic lateral sclerosis ALS

B lymphocyte stimulator BlyS

Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.

Matching News

[Comment] The systematic search for risk factors in multiple sclerosis

Substantial advances in multiple sclerosis research have occurred in recent years, from the advent of oral therapies for relapsing-remitting multiple sclerosis1 to the discovery of previously unknown ...

Two Ways Yoga Can Help Benefit Multiple Sclerosis

March has been proclaimed Multiple Sclerosis Awareness Month, spotlighting MS awareness, support and resources. Multiple sclerosis (MS) is a chronic disease of the nervous system that affects differen...

Multiple sclerosis: First evidence of a rogue protein

A rogue protein has been identified in multiple sclerosis, which attacks the body's central nervous system. Reporting for the first time, researchers believe this finding could pave the way for better...

Multiple Sclerosis Partnering 2009-2014

Recently added to the BioPortfolio report store, Multiple Sclerosis Partnering 2009-2014 is a new report from Current Partnering published on 2014-10-31. This 150+-page report is available from $995....

New research finds the first evidence of a rogue protein in multiple sclerosis

In a new study published today in the journal Frontiers in Neurology, a team of researchers led by the University of Surrey, have identified a rogue protein in multiple sclerosis, which attacks the bo...

Despite risks, benzodiazepine use highest in older people

Prescription use of benzodiazepines—a widely used class of sedative and anti-anxiety medications—increases steadily with age, despite the known risks for older people, according to a comprehensive...

10 facts about multiple sclerosis

Multiple sclerosis is the most common neurological disease in young adults, usually striking between the ages of 20 and 40 years.

Takeda files NDA for multiple sclerosis drug in Japan

Biospectrum Developed by Teva Pharmaceutical, glatiramer acetate is indicated for the relapse prevention of multiple sc...

Matching PubMed Articles

Immunopathology of multiple sclerosis.

Multiple sclerosis is an inflammatory demyelinating disease affecting the central nervous system and considered one of the leading causes of disability in young adults. The precise cause of multiple s...

School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis.

For many years, cognitive impairment has been established as a well-known symptom of multiple sclerosis. Moreover, we know that it was present even at the beginning of the disease.

Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study.

Fatigue is one of the most common and disabling symptoms of multiple sclerosis (MS); however, there is no medication that has been approved specifically to treat MS-related fatigue.

Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity.

Memory impairment is frequent in multiple sclerosis (MS), but it is unclear what functional brain changes underlie this cognitive deterioration.

Prevalence of multiple sclerosis among immigrants in Norway.

Multiple sclerosis (MS) prevalence is unevenly distributed worldwide. Immigration to Norway from countries with a lower MS prevalence is increasing. The aim of this study was to investigate MS prevale...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement